Skip to main content
Caplight Logo









Nanjing Zaiming Pharmaceutical Co., Ltd.

Nanjing Zaiming Pharmaceutical Co., Ltd.

Private
NanjingHealthcare & Life Scienceshttps://www.medchemexpress.cn/

Last Round

Series A

Jun 1, 2025

Est. Valuation

$1.19B

Total Funding Raised

$149M

Company Overview

Nanjing Zaiming Pharmaceutical Co., Ltd. is a pharmaceutical company that focuses on the research and development of innovative oncology therapies, including WRN inhibitors and antibody-based treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

oncologybiopharmaceuticalcancer therapeuticscancer drugsbiologicssmall moleculesADCantibody-drug conjugatePD-L1 inhibitorclinical trialsdrug discoveryanti-angiogenicmyeloprotective agentprecision medicinepharma licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nanjing Zaiming Pharmaceutical Co., Ltd. Comparables

Compare Nanjing Zaiming Pharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.

Nanjing Zaiming Pharmaceutical Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innovent Biologics
78%
CStone Pharmaceuticals
77%
Zai Lab Limited
74%

Nanjing Zaiming Pharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 1, 2025

Nanjing Zaiming Pharmaceutical Co., Ltd. Investors

Notable investors and investment history

Nanjing Zaiming Pharmaceutical Co., Ltd. investors
InvestorRounds
Zhonghe CapitalSeries A
Apricot CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    $149M round led by Advanced Manufacturing Industry Investment Fund II.

Nanjing Zaiming Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nanjing Zaiming Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nanjing Zaiming Pharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Year FoundedN/A
Last FundingJun 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?